Nanoparticle Formulated Vaccines: Opportunities and Challenges
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 1662
Special Issue Editors
Interests: immunology; mitochondria research
Special Issue Information
Dear Colleagues,
Post-COVID-19, there has been an explosion of interest in nanoparticulate-based vaccine technologies for immunization. The multidisciplinary nature of the development process for nanoparticulate systems for vaccines is challenging due to their intrinsic complexity. We are glad to announce this Special Issue, "Nanoparticle Formulated Vaccines: Opportunities and Challenges", of the journal Vaccines. This Special Issue covers recent advances in the design of efficient nanoparticulate vaccines against emergent infectious pathogens. This Special Issue will encompass vaccine preparation along with the merits and demerits of various nanoparticulate vaccine formulations in the field of vaccine technology. We hope this Special Issue will be able to address key areas of future research as well as highlighting current emerging technologies in the preclinical and clinical development of safe and effective vaccines. We will collect articles from top researchers describing new approaches or new cutting-edge developments in the field of nanoparticulate formulations of vaccines against infectious diseases. We welcome the submission of manuscripts for this issue.
Dr. Edmund Carvalho
Dr. Amrita Sarkar
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanotherapy
- vaccine development
- immunology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
